ERLEADA® for Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

Among all AR inhibitors FDA approved to treat nmCRPC:

ERLEADA® is the FIRST AND ONLY to deliver a 2-year improvement in median MFS

(ERLEADA® + ADT vs placebo + ADT; 40.5 months vs 16.2 months; HR=0.28; 95% CI: 0.23, 0.35; P<0.0001)1

ERLEADA® improved median overall survival by 14 months:

ERLEADA® is the FIRST AND ONLY therapy to improve median overall survival by more than 1 year in nmCRPC

(ERLEADA® + ADT vs placebo + ADT; 73.9 months [6.2 years] vs 59.9 months [5 years]; HR=0.78; 95% CI: 0.64, 0.96; P=0.0161)*1

SPARTAN Primary Publication

Review the journal article to learn more about the study results

Accessing this article may require a subscription to The New England Journal of Medicine.


SPARTAN Final Analysis Publication

Review the journal article to learn more about overall survival data in the SPARTAN study

Accessing this article may require a subscription to European Urology.


Exploratory Analysis:

SPARTAN Patient-Reported Outcomes Publication

Review the journal article to learn more about patient-reported outcomes in the SPARTAN study

Accessing this article may require a subscription to The Lancet Oncology.

*Secondary endpoint.

ADT = androgen deprivation therapy; CI = confidence interval; FDA = US Food and Drug Administration; HR = hazard ratio; MFS = metastasis-free survival; nmCRPC = non-metastatic castration-resistant prostate cancer; SPARTAN = Selective Prostate Androgen Receptor Targeting with ARN-509.

Reference

1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.